Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Utah Medical Products, Inc. UTMD

Healthcare — Medical Instruments & Supplies
Dividend Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
7.04%

Capital & Financial Ratios

Market Cap
236.21
Revenue
36.11
Net Income
10.49
Free Cash Flow
11.45
Net Debt
(87.53)
Current Ratio
48.62
Debt/Equity
0.00
P/E ratio
22.55
P/S ratio
6.52
P/B ratio
1.93
Past 5Y EPS Growth
0.11%
This Y EPS Growth
—
Next Y EPS Growth
—
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.25
Annual Dividend Rate
1.18
Annual Dividend Yield
1.60%
total individual payouts
2026 0.93
—
—
—
2025 1.23
—
—
—
—
2024 1.21
—
—
—
—
2023 1.19
—
—
—
—
2022 1.17
—
—
—
—
2021 0.86
—
—
—
—
2020 1.13
—
—
—
—
2019 1.11
—
—
—
—
2018 1.09
—
—
—
—
2017 1.07
—
—
—
—
2016 1.05
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 92.87 82.98 85.76 87.53
Receivables 3.39 4.09 3.52 3.57
Inventory 9.58 8.81 7.94 9.00
Other — — — —
106.27 96.33 97.74 100.64
2023 2024 2025 Q'26
Payables 0.77 0.70 0.91 0.88
ST’ Debt — — — —
Other — — — —
4.71 3.76 2.60 2.07
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 8.72 8.53 — —
—
’25 9.71 9.95 9.81 9.05
38.52
’24 11.34 10.40 10.01 9.16
40.90
’23 12.52 12.87 12.51 12.33
50.22
’22 12.32 13.43 12.96 13.58
52.28
’21 10.96 12.60 12.57 12.91
49.05
’20 10.90 8.79 10.48 12.01
42.18
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 3.11 1.38 — —
—
’25 4.46 2.87 3.88 3.48
14.69
’24 5.28 2.76 3.86 2.94
14.83
’23 6.92 4.91 5.12 5.33
22.28
’22 5.05 4.83 5.59 5.68
21.15
’21 5.53 4.69 5.99 4.99
21.20
’20 5.67 3.68 5.01 5.78
20.14
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 2.98 1.25 — —
—
’25 4.28 2.82 3.85 3.37
14.32
’24 5.28 2.65 3.77 2.93
14.62
’23 6.87 4.59 4.94 5.24
21.64
’22 4.81 4.61 5.27 5.64
20.33
’21 5.52 4.48 5.91 4.73
20.65
’20 5.22 3.42 4.91 5.72
19.28
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.82 0.84 — —
—
’25 0.92 0.94 0.82 0.80
3.48
’24 1.09 0.98 1.02 0.86
3.96
’23 1.16 1.15 1.08 1.18
4.57
’22 0.96 1.12 1.18 1.25
4.52
’21 0.83 0.94 1.15 1.13
4.04
’20 0.84 0.36 0.80 0.93
2.94

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80.10 75.00 60.39 51.26 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 109.50 101.41 85.76 65.56 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 221 190 167 152 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.24 0.26 0.24 0.25 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.28 50.22 40.90 38.52 — — —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 61.58% 59.81% 59.03% 57.12% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.66 20.09 16.80 14.11 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.52% 40.00% 41.08% 36.63% — — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.47 16.64 13.87 11.29 — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.08 6.37 2.85 3.01 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.37 13.84 11.68 11.89 — — —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 4.52 4.57 3.96 3.48 — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.81 6.14 4.23 4.53 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.22) (0.18) (0.06) (0.11) — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.59 5.96 4.17 4.42 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.41 35.36 33.52 36.81 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.64 3.63 3.50 3.24 — — —
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.68 18.27 15.56 16.08 — — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.80 6.03 5.26 4.71 — — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.11 2.36 1.83 1.52 — — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.37 4.19 3.24 2.49 — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.82 9.72 9.08 6.70 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.15 22.28 14.83 14.69 — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.82) (0.64) (0.21) (0.37) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.33 21.64 14.62 14.32 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.96 101.56 92.57 95.14 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.40 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.66) (92.87) (82.98) (85.76) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 114.25 128.31 117.43 119.27 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.76% 12.83% 10.76% 9.21% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.24% 29.58% 24.66% 21.26% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.88% 13.72% 11.29% 9.54% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Utah Medical Products, Inc. (UTMD) has long been a haven for conservative investors, boasting a pristine balance sheet with $83 million in net cash—over 200% of 2024 revenue—and consistent high margins averaging 40% EBT. Yet, the company’s niche in single-use neonatal, OB/GYN, and electrosurgery devices faces cyclical headwinds, exemplified by a steep 19% revenue plunge to $40.9 million in 2024, echoing but surpassing the 2020 COVID dip. Stable revenue per employee around $245,000 underscores operational efficiency amid a 12% headcount cut, but profitability slipped with EPS down 13% to $3.96 and ROE at 11.3%.

Cash flow remains a bulwark, with free cash flow per share steady at $4.17 despite softer operating cash, funding buybacks and dividends without debt. Valuations have compressed to decade lows—P/E 15.6x, EV/FCF 9x—offering a margin of safety after stock prices retreated 30% from 2021 peaks, mirroring revenue weakness. Muted insider activity and analyst targets implying just 2% upside reflect tempered expectations for a procedural rebound.

In this high-rate environment, UTMD’s fortress-like finances provide downside protection for patient portfolios, but prolonged healthcare austerity poses risks to margins and growth. A hold for yield-focused strategies merits monitoring Q1 2025 for stabilization signals—echoing historical cycles where balance sheets outlasted temporary storms.

Read full commentary →

Utah Medical Products, Inc. (UTMD) Latest News

News by impact score

Fine-tune

15 Sep

4 , 10:00 AM
Utah Medical Products, Inc. (UTMD) announces a self-tender offer to repurchase 20% of its shares. Self-tender for 20% of shares is a major capital allocation move that can alter share count, EPS, and investor sentiment.

31 Aug

3 , 9:00 AM
Femcare Ltd acquires Orion Medical Supplies Ltd in the UK. Acquisition by subsidiary expands UK market presence with moderate revenue and positioning effects.

29 Jul

3 , 1:39 PM
Utah Medical Products reported lower Q2 earnings year-over-year due to customer losses. Customer losses causing reduced earnings point to ongoing revenue pressure that could affect financial results and investor views.

23 Jul

3 , 9:00 AM
Utah Medical Products reported financial performance for the second calendar quarter and first half of 2026. Quarterly financial results often drive short-term stock movements and investor views on company health.

23 Apr

3 ACCESS Newswire, 9:00 AM
Utah Medical Products, Inc. (UTMD) reported financial performance for the first quarter of 2026. Quarterly financial results moderately influence UTMD's financial performance and market sentiment.

4 Feb

3 ZacksAssociated Press FinanceMedical Device NetworkZacksZacks, 12:38 PM
Utah Medical Products, Inc. (UTMD) reported a decline in Q4 earnings, primarily attributed to a decrease in original equipment manufacturer (OEM) sales. Year-over-year comparisons showed a significant drop in revenue, raising concerns about the company's financial performance and market position. The decline in OEM sales has prompted analysts to reassess future growth prospects for UTMD, indicating potential challenges ahead. The decline in OEM sales is expected to moderately influence financial performance and market sentiment.

29 Jan

4 , 9:00 AM
Utah Medical Products, Inc. (UTMD) reported its financial performance for the year 2025 and the fourth quarter, highlighting significant revenue growth and improved profitability. The company attributed its success to increased demand for its medical devices and effective cost management strategies. Additionally, UTMD announced plans for new product launches and expansion into international markets, aiming to enhance its competitive position in the healthcare sector. The announcement of new product launches and international expansion is likely to significantly impact future performance and investor sentiment.

25 Jan

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 8:15 AM
Utah Medical Products, Inc. (UTMD) has seen a significant rise in its stock price, but its financial performance appears inconsistent. Analysts are questioning whether this upward trend will be sustainable given the mixed financial indicators. Investors are advised to consider the potential risks and rewards associated with the company's current trajectory. Inconsistent financial performance may moderately influence investor sentiment and future market positioning.

28 Dec

3 Simply Wall St., 7:51 AM
Utah Medical Products, Inc. (UTMD) has struggled to enhance its returns, with recent performance indicating stagnation rather than growth. Despite efforts to innovate and expand, the company's financial metrics suggest a lack of acceleration in profitability and market position. Investors are concerned about the future trajectory as the competitive landscape evolves, and UTMD's inability to adapt may hinder its long-term success. Stagnation in returns and performance metrics may moderately influence investor sentiment and future financial performance.

11 Dec

3 Simply Wall St., 5:16 AM
Utah Medical Products, Inc. (UTMD) has been analyzed for its intrinsic value, considering various financial metrics and market conditions. The evaluation includes an assessment of the company's earnings, growth potential, and competitive positioning within the medical device industry. Key factors influencing UTMD's valuation include its product portfolio, market demand, and operational efficiency. The analysis aims to provide insights for investors regarding the company's future performance and investment potential. The analysis highlights key financial metrics and market conditions that may moderately influence UTMD's future performance.

8 Nov

3 Simply Wall St., 7:11 AM
Utah Medical Products, Inc. (UTMD) has announced an increase in its quarterly dividend to $0.31 per share, reflecting the company's commitment to returning value to shareholders. This decision underscores the company's strong financial position and ongoing profitability. The dividend increase indicates financial stability and may positively influence investor sentiment, but it is not expected to fundamentally alter the company's trajectory.

4 Nov

3 , 10:00 AM
Utah Medical Products, Inc. has appointed a new director to its board and announced an increase in its quarterly dividend. The company aims to enhance its governance and return value to shareholders through this dividend hike. The appointment of a new director and dividend increase may positively influence investor sentiment and financial performance but are not expected to significantly alter the company's overall trajectory.

29 Oct

3 Zacks, 1:29 PM
Utah Medical Products, Inc. (UTMD) reported a year-over-year decline in Q3 earnings, attributed to trade disruptions and squeezed margins. The company faced challenges in its supply chain and increased costs, impacting profitability. Despite these issues, UTMD remains focused on its long-term strategies and product development. Earnings decline due to trade disruptions and margin pressures may moderately affect financial performance and investor sentiment.

24 Oct

3 Simply Wall St., 9:15 PM
Utah Medical Products, Inc. (UTMD) is facing challenges as its profit margins decline, raising concerns about its reputation for delivering high-quality earnings. The company has reported a decrease in margins, which could impact investor confidence and market perception. Analysts are closely monitoring these developments as they may influence UTMD's financial stability and growth prospects in the competitive medical products sector. Margin declines could moderately affect financial performance and investor sentiment.

23 Oct

4 Associated Press FinanceSimply Wall St.Associated Press FinanceAssociated Press FinanceMT NewswiresMT NewswiresAssociated Press FinanceZacks, 9:08 AM
Utah Medical Products, Inc. (UTMD) reported its Q3 earnings, highlighting a revenue increase and improved net income compared to the previous year. The company attributed this growth to strong demand for its medical devices and effective cost management strategies. Additionally, UTMD announced plans for future product innovations and market expansion, aiming to enhance its competitive position in the healthcare sector. The company's revenue growth and plans for product innovation indicate a significant impact on its future performance and market positioning.

4 ACCESS Newswire, 9:00 AM
Utah Medical Products, Inc. (UTMD) reported its financial performance for the third calendar quarter and the first nine months of 2025, highlighting revenue growth and improved profitability. The company experienced an increase in sales driven by strong demand for its medical devices. Additionally, UTMD's operational efficiency contributed to a rise in net income compared to the previous year. The report indicates a positive outlook for the remainder of the year, with expectations for continued growth in key markets. The financial performance report indicates significant revenue growth and improved profitability, suggesting a positive shift in the company's trajectory.

5 Oct

4 Simply Wall St., 8:52 AM
Utah Medical Products, Inc. (UTMD) has a strong institutional backing, with 65% of its shares owned by institutional investors. This significant ownership indicates confidence in the company's stability and growth potential. The support from these institutions may enhance UTMD's market credibility and attract further investment, positioning the company favorably in the medical products sector. The substantial institutional ownership is likely to influence investor sentiment and market performance significantly.

18 Aug

3 Simply Wall St., 8:12 AM
Utah Medical Products, Inc. (UTMD) faces a mixed outlook as its fundamentals show both strengths and weaknesses. While the company has a solid product portfolio and a history of profitability, concerns about its growth potential and market competition persist. Analysts are divided on whether UTMD can maintain its performance amidst these challenges, leading to uncertainty regarding its future trajectory. Moderate concerns about growth potential and competition may influence financial performance.

1 Aug

3 Simply Wall St., 9:15 AM
Utah Medical Products, Inc. (UTMD) has confirmed its quarterly dividend of $0.305 per share, reflecting the company's commitment to returning value to its shareholders. The dividend will be payable on December 1, 2023, to shareholders of record as of November 17, 2023. This decision underscores the company's stable financial position and ongoing dedication to maintaining shareholder returns. Affirming the dividend indicates financial stability but does not significantly alter the company's overall trajectory.

30 Jul

3 Zacks, 12:59 PM
Utah Medical Products, Inc. (UTMD) reported a decline in Q2 earnings year-over-year, primarily attributed to decreasing OEM sales. As a result, the company's stock fell by 3%. Falling OEM sales may moderately affect financial performance and market sentiment.

25 Jul

4 , 7:06 AM
Utah Medical Products, Inc. (UTMD) reported its Q2 earnings, showing a notable increase in revenue and net income compared to the previous year. The company attributed this growth to strong demand for its medical devices and effective cost management strategies. Additionally, UTMD announced plans for new product launches aimed at expanding its market presence. The outlook for the remainder of the year remains positive, with expectations for continued growth driven by innovation and market expansion efforts. Significant growth in revenue and plans for new product launches indicate a strong potential for future performance.

24 Jul

4 , 9:00 AM
Utah Medical Products, Inc. (UTMD) reported its financial performance for the second quarter and first half of 2025, highlighting revenue growth and improved profitability. The company experienced an increase in sales driven by strong demand for its medical devices. Key financial metrics showed positive trends, with net income rising compared to the previous year. Management expressed optimism about future growth prospects and ongoing product development initiatives. The report reflects UTMD's solid position in the medical device market and its commitment to innovation. The financial performance report indicates significant growth and strategic initiatives that could alter the company's trajectory.

25 Jun

3 , 12:40 PM
Utah Medical Products, Inc. (UTMD) is evaluated for its fair value, considering its financial performance, market position, and growth potential. The analysis highlights key metrics and compares them to industry standards, providing insights into the company's valuation. Factors influencing UTMD's market performance include product innovation and competitive landscape dynamics, which are essential for investors to consider when assessing the company's future prospects. Moderate influence is expected due to the company's financial performance and market positioning.

23 May

3 , 7:19 AM
Utah Medical Products, Inc. (UTMD) reported disappointing earnings, raising concerns among investors. However, there are indications of potential recovery, including new product developments and market opportunities that could improve future performance. Analysts suggest that while the current results are underwhelming, strategic initiatives may lead to a more favorable outlook. New product developments and market opportunities may moderately influence future performance.

5 May

3 Zacks, 1:35 PM
Utah Medical Products, Inc. (UTMD) reported a 16% decline in Q1 earnings per share to 92 cents, with net sales dropping 14.4% to $9.7 million. The decrease in earnings was partially offset by a reduced share count from repurchases. Gross profit fell 18.1% to $5.5 million, and operating income decreased 18.8% to $3.2 million. Domestic direct sales rose 11.6%, driven by demand for NICU devices, but were overshadowed by a 61.3% drop in U.S. OEM sales, primarily from PendoTECH. Management noted a higher effective tax rate and did not issue specific financial forecasts but expects revenue and gross margin levels to remain consistent. UTMD repurchased shares and maintained a strong financial position with cash and investments totaling $83.3 million. The significant drop in sales and earnings, particularly from key customers, indicates a moderately noticeable influence on future performance.

1 May

3 Simply Wall St., 8:09 AM
Utah Medical Products, Inc. (UTMD) reported earnings for the first quarter of 2025, with earnings per share (EPS) at $0.92, a decline from $1.09 in the same quarter of 2024. The decrease in EPS indicates potential challenges in maintaining profitability compared to the previous year. The decline in EPS suggests moderate financial challenges that could affect investor sentiment and operational performance.

29 Apr

4 Associated Press Finance, 9:07 AM
Utah Medical Products, Inc. (UTMD) reported its Q1 earnings, highlighting a revenue increase and improved net income compared to the previous year. The company attributed this growth to strong demand for its medical devices and effective cost management strategies. Additionally, UTMD announced plans for future product innovations and market expansion, aiming to enhance its competitive position in the healthcare sector. The company's plans for product innovations and market expansion are likely to significantly impact its future performance and investor sentiment.

4 ACCESS Newswire, 9:00 AM
Utah Medical Products, Inc. reported its financial performance for the first quarter of 2025, highlighting key metrics such as revenue growth and net income. The company experienced an increase in sales driven by strong demand for its medical devices. Management expressed optimism about future growth prospects and outlined strategic initiatives aimed at enhancing product offerings and expanding market reach. Overall, the results reflect a positive trajectory for the company in a competitive landscape. The financial performance indicates significant growth and strategic initiatives that could alter the company's trajectory.

28 Apr

3 , 7:06 AM
Utah Medical Products, Inc. (NASDAQ:UTMD) has 65% institutional ownership, indicating significant influence over its share price. Thirteen investors hold a majority stake, with hedge funds owning 6.7%. The largest shareholder is Renaissance Technologies LLC. Insider ownership is valued at $12 million, while the general public holds 22%. Despite institutional backing, caution is advised as their decisions can impact stock prices. Analyst coverage is currently absent, suggesting limited market interest. Institutional ownership indicates credibility and potential influence on stock performance, but the lack of analyst coverage suggests limited immediate impact.

7 Apr

3 , 8:47 AM
Utah Medical Products, Inc. (UTMD) reported soft earnings that, upon closer examination, reveal underlying strengths. Despite a decline in revenue and net income, the company demonstrated resilience through cost management and strategic investments. Analysts suggest that the earnings miss may not reflect the company's long-term potential, as it continues to innovate and expand its product offerings. The market's initial negative reaction may be overblown, as UTMD's fundamentals remain solid, positioning it well for future growth. Earnings performance indicates some challenges, but the company's strategic positioning and innovation efforts suggest a balanced outlook.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us